Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma.

Takeshi SuzukiAkihiko OkamuraMasayuki WatanabeShinji MineYu ImamuraTakao AsariHiroki OsumiIzuma NakayamaTakashi IchimuraMariko OguraAkira OokiDaisuke TakahariKensei YamaguchiKeisho Chin

Published in: Annals of surgical oncology (2019)

Curative resection was achieved for about 40% of the patients who received NACRT for BR-ESCC. Therefore, NACRT could be a useful neoadjuvant treatment option for BR-ESCC. However, a higher serum SCC antigen level before NACRT is predictive of treatment failure and poor survival.

Keyphrases

rectal cancer
locally advanced
lymph node
squamous cell carcinoma
radiation therapy
combination therapy
replacement therapy